It's still less invasive than what Omni was doing, given Omni actually tears the canal on the way out (trabeculotomy). Doctors still rapidly adopted that...
If ab externo gets pulled from the LCD, it wont be for another 2+ years (the MACs are slow to make changes). By then the company will have sufficient data (trials have already commenced) to get full and unrestricted coverage for all methods, so it won't matter
In the meantime, iTrack will be the only procedure which can still be used for canaloplasty (which still has significantly more favourable reimbursement than stents). This will secure us a spot as the market leader, as Omni wont be reimbursed full stop as it was specifically labeled as non covered
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)